PET/MR in Radiotherapy for Head and Neck Cancer Pilot
An Exploratory Study to Assess the Feasibility of Incorporating PET/MR in the Radiotherapy Pathway of Patients With Head and Neck Cancer and Guide Adaptive Dose Escalation
1 other identifier
interventional
8
1 country
1
Brief Summary
This is a pilot non-intervention study that aims to introduce PET/MRI, a state of the art new imaging technique, into the radiotherapy treatment pathway of patients with head and neck cancer. Ultimately the investigators aim to establish appropriate scanning and image registration protocols, to allow progression to a randomized trial of adaptive radiotherapy dose escalation. The latter is thought to potentially improve outcomes in this group. Ten patients with squamous cell carcinoma (SCC) of the oropharynx, hypopharynx and larynx, planned for radical treatment with radiotherapy (+/-chemotherapy), will be recruited. Study participants will have two PET/MRI scans, with the radiotherapy immobilization devices in situ. The first will be done prior to the start of radiotherapy, the second half way through treatment. Image quality will be assessed by comparing to standard diagnostic scans and different registration methods will be compared to establish the best way of incorporating PET/MR image data into the radiotherapy planning system. Patient tolerability and workflow considerations will also be qualitatively assessed. Furthermore, a planning study will be conducted to establish relevant treatment protocols for a subsequent dose escalation trial. PET/MRI is an exciting new technology with a lot of potential in the context of adaptive radiotherapy dose escalation. Within this pilot study the investigators aim to address the technical challenges of using it in this context prior to proceeding to a randomized trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable head-and-neck-cancer
Started Apr 2016
Shorter than P25 for not_applicable head-and-neck-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2016
CompletedFirst Submitted
Initial submission to the registry
October 25, 2016
CompletedFirst Posted
Study publicly available on registry
November 2, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedAugust 29, 2019
August 1, 2019
1.3 years
October 25, 2016
August 27, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of scans where image quality is sufficient to characterise the primary tumour, assessed qualitatively by an experienced radiologist and oncologist
6 months following study completion
Proportion of patients that tolerated the full scanning protocol, assessed by tailored patient questionnaire
6 months following study completion
Study Arms (1)
Single arm imaging study
OTHERSingle arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
Interventions
Eligibility Criteria
You may qualify if:
- Written, voluntary, informed consent
- Age ≥ 18
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- Life expectancy \> 12 months
- Histologically proven SCC of the oropharynx, hypopharynx and larynx
- Radical radiotherapy +/- chemotherapy indicated as the primary treatment modality
- Visible disease (\>1cm) at the primary site on any imaging modality performed within 4 weeks of starting radiotherapy treatment
- Staging PET/CT and diagnostic MRI of the head and neck images need to be available for comparison.
- Adequate organ function and absence of other major concurrent illness, allowing the patient to tolerate scanning regime
You may not qualify if:
- Inability to provide informed consent
- Impaired renal function (serum creatinine of \> 200)
- Severely impaired liver function
- Patients with allergies or contra-indications to the radio-tracer and/or contrast agent used in the study
- Severe claustrophobia or inability to tolerate PET or MRI scans
- General contra-indications to MRI, as defined in MRI safety departmental protocols
- Serious inter-current conditions or other non-malignant illnesses that are uncontrolled or whose control may be affected by participation in this study
- Any patient who has urinary or faecal incontinence
- ECOG Performance Status ≥ 3
- Pregnant or breastfeeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Teresa Guerrero Urbano
Guy's & St Thomas' NHS Foundation Trust, London, UK
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 25, 2016
First Posted
November 2, 2016
Study Start
April 1, 2016
Primary Completion
August 1, 2017
Study Completion
August 1, 2017
Last Updated
August 29, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share